Arcutis Launches First-in-Human Trial of CD200R Agonist ARQ-234 in Atopic Dermatitis

Key Takeaways

• Arcutis announced its first-in-human phase 1a/1b trial of ARQ-234, a CD200R agonist, in healthy volunteers and adults with moderate to severe atopic dermatitis (AD).

• The randomized, double-blind, placebo-controlled study will evaluate single- and multiple-ascending doses, followed by a small proof-of-concept cohort in AD.

• ARQ-234 is a fusion protein that activates the CD200 receptor.

Arcutis Biotherapeutics announced today that it has enrolled the first participant in a phase 1a/1b clinical trial evaluating ARQ-234, an investigational CD200 receptor (CD200R) agonist, in healthy volunteers and adults with moderate to severe atopic dermatitis (AD).

According to a press release from the manufacturer, the first-in-human study (ARQ-234-131) is a randomized, double-blind, placebo-controlled trial asessing safety and tolerability of ARQ-234 administered via subcutaneous injection. The study includes sequential single-ascending-dose cohorts in healthy volunteers and adults with moderate to severe AD, followed by multiple-ascending-dose cohorts and a small proof-of-concept cohort in adults with AD.

Arcutis noted that the investigational biologic is a fusion protein engineered to selectively activate CD200R, an immune-regulatory checkpoint that modulates inflammatory responses. By targeting CD200R, they said, the therapy is intended to dampen overactive immune signaling and restore immune balance.

“There is a significant opportunity to advance new treatments for moderate to severe atopic dermatitis that address the underlying immune dysregulation and provide long-term symptom control,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis, said in the press release. “We believe ARQ-234 and its CD200R immune-checkpoint agonist mechanism is a very promising pathway to address critical unmet needs.”

Source: Arcutis press release. March 3, 2026.